Thermo Fisher Q4 Earnings Beat Consensus, Clocks COVID-19 Revenue Of $2.45B

Thermo Fisher Scientific Inc TMO has posted Q4 revenues of $10.70 billion, up 1% Y/Y, beating the consensus of $9.29 billion.

  • Organic revenue decreased 4%, acquisitions increased revenue by 6%, and currency translation decreased revenue by 1%.
  • Organic growth from the base business was 8%. COVID-19 response revenue was $2.45 billion.
  • Revenue from Life Sciences Solutions Segment declined 5% to $4.15 billion, Analytical Instruments Segment sales were up 5.4% to $1.72 billion, Specialty Diagnostics Segment revenues decreased 26.4% to $1.45 billion, and Laboratory Products & Services Segment sales were up 16% to $4.19 billion.
  • Adjusted EPS decreased 7.8% to $6.54, ahead of the consensus of $5.26. 
  • Adjusted operating margin contracted from 33.3% a year ago to 29.5%.
  • Price Action: TMO shares closed at $594.31 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!